ArticleACS chemical biology2018
A Switchable Site-Specific Antibody Conjugate.
Article in ACS chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates.Cell reports methods · 2026Article
- Adapter-based allogeneic CAR T cells to overcome antigen escape in solid tumors.Frontiers in immunology · 2026Review
- Engineering Hepatitis B Virus (HBV) Protein Particles for Therapeutic Delivery.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Introduction of Carbonyl Groups into Antibodies.Molecules (Basel, Switzerland) · 2023Review
- Site-specific protein conjugates incorporating Para-Azido-L-Phenylalanine for cellular and in vivo imaging.Methods (San Diego, Calif.) · 2023Article
- Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).Molecular and clinical oncology · 2023Review
- Engineering protein-based therapeutics through structural and chemical design.Nature communications · 2023Review
- Making Sense of "Nonsense" and More: Challenges and Opportunities in the Genetic Code Expansion, in the World of tRNA Modifications.International journal of molecular sciences · 2022Review
- Strategies for Multienzyme Assemblies.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Antibody-drug conjugates: Recent advances in linker chemistry.Acta pharmaceutica Sinica. B · 2021Review
- Site-specific antibody fragment conjugates for targeted imaging.Methods in enzymology · 2020Article
- Site-Specific Immuno-PET Tracer to Image PD-L1.Molecular pharmaceutics · 2019Article
- Therapeutic applications of genetic code expansion.Synthetic and systems biotechnology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Genetic incorporation of unnatural amino acids (UAAs) provides a unique approach to the synthesis of site-specific antibody conjugates that are homogeneous and better defined constructs than random conjugates. Yet, the yield varies for every antibody, and the process is costly and time-consuming. We have developed a switchable αGCN4-Fab conjugate that incorporates UAA p-acetylphenylalanine. The GCN4 peptide is used as a switch, and antibodies fused by GCN4 can direct the αGCN4-Fab conjugate to target different cancer cells for diagnosis, imaging, or therapeutic treatment. More importantly, this switchable conjugate demonstrated an impressive potential for pretargeted imaging in vivo. This approach illustrates the utility of an orthogonal switch as a general strategy to endow versatility to a single antibody conjugate, which should facilitate the application of UAA-based site-specific conjugates for a host of biomedical uses in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.